Challenges And Solutions in Rare Disease Treatment: Value-Based Healthcare
DOI:
https://doi.org/10.54097/24vg1y76Keywords:
Rare disease; value-based healthcare; cost-sharing.Abstract
This study is based on the realities of challenges within the field of rare disease treatment, as well as the concept of value-based healthcare. By analyzing treatment plans, rehabilitative care, cost-sharing, prospects for drug development markets and investment returns, as well as policy support, the paper delves into the complexities and diversities of rare disease treatment. Within the research, the focus is on the challenges of rare disease treatment, leveraging the principles of value-based healthcare. It discusses how personalized treatment plans, interdisciplinary collaboration, and reasonable cost-sharing can enhance patient treatment outcomes and quality of life. The article employs methods such as literature reviews and case analyses to deeply explore and analyze rare disease treatment from various angles. The research findings indicate that personalized treatment plans and interdisciplinary collaboration can significantly enhance treatment outcomes and quality of life for rare disease patients. Reasonable cost-sharing models and trends in drug development markets present opportunities for the sustainable growth of the rare disease field. Additionally, policy support and international cooperation mechanisms play vital roles in advancing rare disease treatment. Based on these research findings, the article proposes future research prospects, including strengthening data collection and analysis, deepening international collaboration, and optimizing drug development strategies.
Downloads
References
Jones A.B, Smith C.D, Johnson E.F. Applications of gene editing in rare disease treatment. Journal of Rare Diseases Research, 2019, 10(2): 135-148.
Smith J.K, Garcia M.L. The role of virtual reality in rehabilitation for rare disease patients. Innovative Healthcare Technologies, 2020, 5(3): 187-200.
Brown R.H, Robinson L.E, Lee S.M. Market trends in orphan drug development. Journal of Pharmaceutical Economics, 2018, 15(4): 421-435.
Robinson M.P, Lee H.L. Drug repurposing strategies for rare disease treatment. Drug Discovery Today, 2021, 26(6): 1365-1372.
Mullins D, Johnson P, Williams K. Regulatory policies for orphan drug approval: A comparative analysis. Regulatory Review, 2017, 12(3): 223-235.
Smith E.R, Johnson L.W. Health insurance policy impact on rare disease patients' access to treatment. Health Policy and Management, 2019, 22(1): 78-89.
National Organization for Rare Disorders (NORD). NORD advances practical, meaningful, and enduring change so people with rare diseases can live their fullest and best lives, 2023.
Boao Winhealth Rare Disease Medical Center. Report and Scientific Knowledge from the Boao Lecheng Rare Disease Clinical Medical Center, 2023.
Hainan Boao Lecheng International Medical Tourism Pilot Zone. Scientific Knowledge from Bo’ao Lecheng International Medical Tourism Pilot Zone, 2023.
Wang S. Understanding the Rare Diseases and Orphan Drugs. Report and Scientific Knowledge from Wang Shuhe Biomedical (Wuhan) Co., Ltd, 2023.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.






